ArticleClinical and experimental nephrology2009
Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.
Article in Clinical and experimental nephrology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- COVID-19 concomitant with infective endocarditis: A case report and review of management.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Review
- Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation.Scientific reports · 2019Article
- Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria.Heart and vessels · 2018Article
- The efficacy of tolvaptan in the perioperative management of chronic kidney disease patients undergoing open-heart surgery.Surgery today · 2017Article
- Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery.General thoracic and cardiovascular surgery · 2017Article
- Copeptin and Decline in Kidney Function.American journal of nephrology · 2016Article
- Echocardiographic characteristics of patients with acute heart failure requiring tolvaptan: a retrospective study.Cardiovascular ultrasound · 2015Article
- Vasopressin receptor antagonists.Current hypertension reports · 2015Review
- Nephrotic syndrome complicated by idiopathic central diabetes insipidus.Pediatric nephrology (Berlin, Germany) · 2014Article
- The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure.Clinical and experimental nephrology · 2013Observational
- Vasopressin: a novel target for the prevention and retardation of kidney disease?Nature reviews. Nephrology · 2013Review
- The reno-protective effect of a phosphoinositide 3-kinase inhibitor wortmannin on streptozotocin-induced proteinuric renal disease rats.Experimental & molecular medicine · 2012Article
- The podocyte as a target for therapies--new and old.Nature reviews. Nephrology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProteinuria caused by glomerular disease is characterized by podocyte injury. Vasopressin V2 receptor antagonists are effective in reducing albuminuria, although their actions on glomerular podocytes have not been explored. The objective of this study was to evaluate the effects of tolvaptan, a selective oral V2 receptor antagonist, on podocytes in a puromycin aminonucleoside (PAN)-induced nephrosis rat model.
methodsRats were allocated to a control, PAN nephrosis, or tolvaptan-treated PAN nephrosis group (n = 9 per group). Urinary protein excretion and serum levels of total protein, albumin, creatinine, and total cholesterol were measured on day 10. The influence of tolvaptan on podocytes was examined in renal tissues by immunofluorescence and electron microscopy.
resultsPAN induced massive proteinuria and serum creatinine elevation on day 10, both of which were significantly ameliorated by tolvaptan. Immunofluorescence studies of the podocyte-associated proteins nephrin and podocin revealed granular staining patterns in PAN nephrosis rats. In tolvaptan-treated rats, nephrin and podocin expressions retained their normal linear pattern. Electron microscopy showed foot process effacement was ameliorated in tolvaptan-treated rats.
conclusionsTolvaptan is protective against podocyte damage and proteinuria in PAN nephrosis. This study indicates that tolvaptan exerts a renoprotective effect by affecting podocyte morphology and probably function in PAN nephrosis. Tolvaptan is a promising pharmacological tool in the treatment of renal edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.